Skip to main content

Ascorbic Acid (Monograph)

Brand name: Ascor
Drug class: Vitamin C
ATC class: A11GA01
VA class: VT400
Chemical name: l-ascorbic acid
CAS number: 50-81-7

Medically reviewed by Drugs.com on Apr 3, 2024. Written by ASHP.

Introduction

An essential water-soluble vitamin; ascorbic acid is the in vivo form of vitamin C.109

Uses for Ascorbic Acid

Scurvy

Prevention and treatment of scurvy.a

Dietary Requirements

Adequate intake needed to prevent scurvy and provide antioxidant protection.109

Adequate vitamin C intake can be accomplished through consumption of foodstuffs.109 Citrus fruits, tomatoes, and potatoes are the major contributors of vitamin C in the diet of US adults and children.109

Recommended Dietary Allowances (RDA) in adults based on near maximal neutrophil concentrations with minimal urinary excretion of ascorbate.109

Requirements slightly lower in women than men based on water-soluble nature of the vitamin and the larger lean body mass and total body water in males relative to females.109

Adequate intake (AI) established for infants ≤6 months of age based on observed mean vitamin C intake of infants fed principally human milk; AI for infants 7–12 months of age based on vitamin C intake from human milk and solid food.109

RDA for children 1–18 years of age based on data in adults.109

Macular Degeneration

Suggested as a component of high-dose antioxidant supplements with zinc to reduce risk of developing advanced age-related macular degeneration [off-label] in high-risk patients (i.e., those with intermediate stage age-related macular degeneration or advanced stage macular degeneration in only one eye).111 112

Respiratory Infections

Large doses have been advocated for lessening severity of and for preventing the common cold [off-label].a Routine supplementation modestly decreases duration of symptoms; also appears to decrease incidence in individuals under heavy physical stress but not in the overall population.202 203 211 No consistent effect on duration or severity of symptoms when initiated following symptom onset.202 211

Limited study data available regarding effects in the prevention or treatment of pneumonia [off-label]; available studies were conducted under specific circumstances and may not be applicable to the general population.202 203

Studies required to establish efficacy of adjunctive ascorbic acid therapy in the treatment of severe viral respiratory infections [off-label].206

Sepsis

High-dose IV ascorbic acid has been evaluated in patients with sepsis [off-label];204 208 209 210 efficacy remains to be established.209 210 212 213

Meta-analysis of several small studies suggested beneficial effects from adjunctive IV ascorbic acid in patients with sepsis, but primary efficacy end points were not improved in 2 subsequent multicenter, randomized studies (CITRIS-ALI, VITAMINS).208 209 210 Additional studies under way.204 213

Methemoglobinemia

Has been used in the treatment of idiopathic methemoglobinemia.a

Ascorbic Acid Dosage and Administration

Administration

Usually administered orally.a May be administered by IM, IV, or sub-Q injection when oral administration is not feasible or when malabsorption is suspected.a

Parenteral Administration

Preferred parenteral method of administration is IM.a

Pressure may build within the vial during storage.b Exercise care when withdrawing a dose and/or insert a vent needle (e.g., empty sterile syringe) into the vial to release the pressure.b

IV Administration

Dilution

For solution and drug compatibility, see Compatibility under Stability.

Dilute with large volume of compatible parenteral fluid to minimize adverse reactions.b Avoid rapid infusion.b

Dosage

Available as ascorbic acid, calcium ascorbate, and sodium ascorbate; dosage expressed in terms of ascorbic acid.b d

Pediatric Patients

Scurvy
Treatment
Oral or IV

100–300 mg daily for 1 month or until full recovery.a c

Dietary and Replacement Requirements
Oral

Infants ≤6 months of age: Recommended AI is 40 mg (about 6 mg/kg) daily.109

Infants 7–12 months of age: Recommended AI is 50 mg (about 6 mg/kg) daily.109

Children 1–3 years of age: RDA is 15 mg daily.109

Children 4–8 years of age: RDA is 25 mg daily.109

Children 9–13 years of age: RDA is 45 mg daily.109

Boys 14–18 years of age: RDA is 75 mg daily.109

Girls 14–18 years of age: RDA is 65 mg daily.109

Adults

Scurvy
Treatment
Oral or IV

300 mg–1 g daily for 1 month or until full recovery.b c

Dietary and Replacement Requirements
Oral

Men ≥19 years of age: RDA is 90 mg daily.109

Women ≥19 years of age: RDA is 75 mg daily.109

Macular Degeneration†
Oral

500 mg in combination with beta carotene 15 mg, vitamin E 400 units, and zinc (as zinc oxide) 80 mg, with copper (as cupric oxide) 2 mg (to prevent anemia) daily has been used.111 112

Respiratory Infections†
Common Cold†
Oral

1–3 g or greater per day has been recommended for prevention and treatment.a

Idiopathic Methemoglobinemia†
Oral

300–600 mg daily in divided doses has been used.a

Special Populations

Pregnant Women

RDA for pregnant women 14–18 years of age is 80 mg daily.109

RDA for pregnant women 19–50 years of age is 85 mg daily.109

Requirements increased in pregnant women to ensure transfer of adequate amounts of the vitamin to the fetus.109

Lactating Women

RDA for lactating women 14–18 or 19–50 years of age is 115 or 120 mg daily, respectively.109

Requirements increased in lactating women to ensure adequate concentration of the vitamin in milk.109

Smokers

RDA increased by 35 mg daily.109

Smoking increases oxidative stress and metabolic turnover of vitamin C.109

Cautions for Ascorbic Acid

Contraindications

Warnings/Precautions

General Precautions

Sodium Content

Each 1 gram of sodium ascorbate contains approximately 5 mEq of sodium; consider sodium content in patients on sodium-restricted diets.a

Kidney Stone Formation

Kidney stone (renal calculus) formation reported in individuals with renal disease receiving large dosages of ascorbic acid; excess ascorbic acid intake not associated with kidney stone formation in healthy individuals.109

Aluminum Content

Some ascorbic acid injection preparations contain aluminum that may be toxic.b Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired.b Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.b

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum >4–5 mcg/kg daily accumulate aluminum at levels associated with CNS and bone toxicity.b Tissue loading may occur at even lower rates of administration.b

Specific Populations

Pregnancy

Category C.b

Lactation

Distributed into milk.a Caution if parenteral preparation is used in nursing women.b

Common Adverse Effects

Relatively nontoxic; nausea, vomiting, heartburn, fatigue, flushing, headache, insomnia, sleepiness, and other GI disturbances (diarrhea, transient colic, abdominal cramps, flatulent distention) reported.a

Drug Interactions

Laboratory Tests

Interferes with numerous laboratory tests based on oxidation-reduction reactions.a Degree of interference depends on several factors (e.g., ascorbic acid concentration, resulting pH, specific reagents).a Consult specialized references.a

Specific Drugs and Laboratory Tests

Drug or Test

Interaction

Comments

Aspirin

Increased urinary excretion of ascorbic acid and decreased excretion of aspirin reported with concomitant administrationa

Fluphenazine

Decreased fluphenazine concentrationsa

Iron, oral

Increased GI absorption of irona

Tests for detection of occult blood in stool

Possible false-negative resultsb

Manufacturer of parenteral ascorbic acid recommends discontinuing vitamin C supplements 48–72 hours before testb

Tests for glucose in urine

Possible false-positive with tests based on cupric sulfate reagent and false-negative with tests that use glucose oxidase methoda

Warfarin

Decreased anticoagulant effect reported; other investigators did not observe this effecta

Ascorbic Acid Pharmacokinetics

Absorption

Bioavailability

Readily absorbed by an active process that may be limited after very large doses.a

Distribution

Extent

Widely distributed in body tissues.a

Crosses the placenta; cord blood concentration 2–4 times maternal blood concentrations.a Distributed into human milk.a

Plasma Protein Binding

About 25%.a

Elimination

Metabolism

Reversibly oxidized to dehydroascorbic acid.a

Elimination Route

Excreted in urine. a

Removed by hemodialysis.a

Stability

Storage

Oral

Capsules and Tablets

Cool dry place.d

Parenteral

Solution

Store in carton until time of use at room temperature (≤25°C).b Protect from light. b

Compatibility

Parenteral

Solution CompatibilityHID

Compatible

Dextran 6% in dextrose 5%

Dextran 6% in sodium chloride 0.9%

Dextrose-Ringer’s injection combinations

Dextrose-Ringer’s injection, lactated, combinations

Dextrose-saline combinations

Dextrose 2½, 5, or 10% in water

Fructose 10% in sodium chloride 0.9%

Fructose 10% in water

Invert sugar 5 and 10% in sodium chloride 0.9%

Invert sugar 5 and 10% in water

Ionosol products

Ringer’s injection

Ringer’s injection, lactated

Sodium chloride 0.45 or 0.9%

Sodium lactate (1/6) M

Variable

Fat emulsion 10%, IV

Drug Compatibility
Admixture CompatibilityHID

Compatible

Amikacin sulfate

Calcium chloride

Calcium gluconate

Chloramphenicol sodium succinate

Chlorpromazine HCl

Colistimethate sodium

Cyanocobalamin

Dimenhydrinate HCl

Heparin sodium

Kanamycin sulfate

Methyldopate HCl

Penicillin G potassium

Polymyxin B sulfate

Procaine HCl

Prochlorperazine edisylate

Promethazine HCl

Verapamil HCl

Incompatible

Bleomycin sulfate

Nafcillin sodium

Sodium bicarbonate

Theophylline

Variable

Aminophylline

Erythromycin lactobionate

Y-Site CompatibilityHID

Compatible

Warfarin sodium

Incompatible

Etomidate

Thiopental sodium

Actions

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Ascorbic Acid (as Ascorbic Acid or Sodium Ascorbate)

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

Parenteral

Injection

500 mg/mL*

Ascor

McGuff

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Calcium Ascorbate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 13, 2020. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

73. Nienhuis A, Delea C, Aamodt R et al. Potential role for desferrioxamine and ascorbic acid in the treatment of chronic iron overload. Blood. 1975. 46:1026. Abstract. (IDIS 64329)

74. Hussain MAM, Flynn DM, Green N et al. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet. 1977; 1:977-9. http://www.ncbi.nlm.nih.gov/pubmed/67469?dopt=AbstractPlus

75. Modell B. Total management of thalassemia major. Arch Dis Child. 1977; 52:489-500. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1544709&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/879834?dopt=AbstractPlus

100. Wolfe L, Olivieri N, Sallan D et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985; 312:1600-3. http://www.ncbi.nlm.nih.gov/pubmed/4000198?dopt=AbstractPlus

101. Marcus RE, Davies SC, Bantock HM et al. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet. 1984; 1:392-3. http://www.ncbi.nlm.nih.gov/pubmed/6141447?dopt=AbstractPlus

102. Borgna-Pignatti C, De Stefano P, Broglia AM. Visual loss in patient on high-dose subcutaneous desferrioxamine. Lancet. 1984; 1:681. http://www.ncbi.nlm.nih.gov/pubmed/6142370?dopt=AbstractPlus

103. Olivieri NF, Buncic R, Chew E et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986; 314:869-73. http://www.ncbi.nlm.nih.gov/pubmed/3485251?dopt=AbstractPlus

104. Nienhuis AW, Benz EJ, Propper R et al. Thalassemia major: molecular and clinical aspects. Ann Intern Med. 1979; 91:883-97. http://www.ncbi.nlm.nih.gov/pubmed/391118?dopt=AbstractPlus

105. Nienhuis AW. Vitamin C and iron. N Engl J Med. 1981; 304:170-1. http://www.ncbi.nlm.nih.gov/pubmed/7442737?dopt=AbstractPlus

106. Pippard MJ, Callender ST, Finch CA. Ferrioxamine excretion in iron-loaded man. Blood. 1982; 60:288-94. http://www.ncbi.nlm.nih.gov/pubmed/7093519?dopt=AbstractPlus

107. Modell B, Petrou M. Management of thalassaemia major. Arch Dis Child. 1983; 58:1026-30. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1628578&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6660889?dopt=AbstractPlus

108. National Research Council Food and Nutrition Board Subcommittee on the Tenth Edition of the RDAs. Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press; 1989:115-24.

109. Committee on the Scientific Evaluation of Dietary Reference Intakes of the Food and Nutrition Board, Institute of Medicine, National Academy of Sciences. Dietary reference intakes for Vitamin C, Vitamin E, selenium, and carotenoids. Washington, DC: National Academy Press; 2000.

110. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes of the Food and Nutrition Board, Institute of Medicine, National Academy of Sciences. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press; 1997. (Uncorrected proofs.)

111. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol. 2001; 119:1417-36. http://www.ncbi.nlm.nih.gov/pubmed/11594942?dopt=AbstractPlus

112. Jampol LM. Antioxidants, zinc, and age-related macular degeneration. Arch Ophthalmol. 2001;119:1533-4. Editorial.

202. Hemilä H. Vitamin C and Infections. Nutrients. 2017; 9 http://www.ncbi.nlm.nih.gov/pubmed/28353648?dopt=AbstractPlus

203. Hemilä H, Louhiala P. Vitamin C for preventing and treating pneumonia. Cochrane Database Syst Rev. 2013; :CD005532. http://www.ncbi.nlm.nih.gov/pubmed/23925826?dopt=AbstractPlus

204. Kashiouris MG, L'Heureux M, Cable CA et al. The Emerging Role of Vitamin C as a Treatment for Sepsis. Nutrients. 2020; 12 http://www.ncbi.nlm.nih.gov/pubmed/31978969?dopt=AbstractPlus

205. Marik PE. Vitamin C: an essential “stress hormone” during sepsis. J Thorac Dis. 2020; 12:S84-S88. http://www.ncbi.nlm.nih.gov/pubmed/32148930?dopt=AbstractPlus

206. Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020; 46:315-328. http://www.ncbi.nlm.nih.gov/pubmed/32040667?dopt=AbstractPlus

208. Li J. Evidence is stronger than you think: a meta-analysis of vitamin C use in patients with sepsis. Crit Care. 2018; 22:258. http://www.ncbi.nlm.nih.gov/pubmed/30305111?dopt=AbstractPlus

209. Fowler AA, Truwit JD, Hite RD et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019; 322:1261-1270. http://www.ncbi.nlm.nih.gov/pubmed/31573637?dopt=AbstractPlus

210. Fujii T, Luethi N, Young PJ et al. Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial. JAMA. 2020; http://www.ncbi.nlm.nih.gov/pubmed/31950979?dopt=AbstractPlus

211. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013; :CD000980. http://www.ncbi.nlm.nih.gov/pubmed/23440782?dopt=AbstractPlus

212. Brant EB, Angus DC. Is High-Dose Vitamin C Beneficial for Patients With Sepsis?. JAMA. 2019; 322:1257-1258. http://www.ncbi.nlm.nih.gov/pubmed/31573621?dopt=AbstractPlus

213. Kalil AC. Lack of Benefit of High-Dose Vitamin C, Thiamine, and Hydrocortisone Combination for Patients With Sepsis. JAMA. 2020; http://www.ncbi.nlm.nih.gov/pubmed/31950983?dopt=AbstractPlus

a. AHFS drug information 2020. Snow EK, ed. Ascorbic Acid. Bethesda, MD: American Society of Health-Systems Pharmacists; .

b. Luitpold Pharmaceuticals, Inc. Ascorbic Acid Injection prescribing information. Shirley, NY; 2000 Jun.

c. Weinstein, M, Babyn P, Zlotkin S. An orange a day keeps the doctor away: scurvy in the year 2000. Pediatrics. 2001; 108:e55.

d. GNC A-Z vitamin C 500 mg tablets package information. Accessed 24 May 2007. http://www.drugstore.com

HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:171-6.